Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Lynette M. Smith

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0836-9932; OpenAlex author ID A5041701143, A5060986528. Sources: OpenAlex.

Their work

Papers
38 (first author 3, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
124
Papers, trials and grants by year

2011: 3 papers · 2012: none · 2013: 1 paper · 2014: 2 papers · 2015: 3 papers · 2016: 4 papers · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: none · 2021: 4 papers · 2022: 4 papers · 2023: 2 papers · 2024: 4 papers · 2025: 1 paper · 2026: 2 papers

Papers 38

  1. Cigarette smoking drives earlier development of pancreatic adenocarcinoma among carriers of hereditary pancreatic cancer susceptibility genes. First author DOI 10.1016/j.pan.2026.05.004↗
  2. Pancreatic Cancer Detection Consortium Biomarker Bakeoff: A Phase II Blinded Biomarker Validation and Panel Discovery Study. Co-author DOI 10.1158/1078-0432.ccr-25-4061↗
  3. Reply to the Letter to the Editor regarding “Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early … First author DOI 10.1016/j.pan.2025.04.017↗
  4. A rigorous multi-laboratory study of known PDAC biomarkers identifies increased sensitivity and specificity over CA19-9 alone. Co-author DOI 10.1016/j.canlet.2024.217245↗
  5. Early detection of pancreatic cancer: Study design and analytical considerations in biomarker discovery and early phase validation studies. Co-author DOI 10.1016/j.pan.2024.10.012↗
  6. Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41698-024-00562-5↗
  7. Pancreatic Cysts Greater Than 1 cm Are Associated With an Increased Risk for Developing Pancreatic Cancer in Individuals From Pancreatic-Cancer Prone Kindreds … Co-author DOI 10.1097/mpa.0000000000002312↗
  8. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising… Co-author DOI 10.1097/sla.0000000000005904↗
  9. A Novel HOXA10-Associated 5-Gene-Based Prognostic Signature for Stratification of Short-term Survivors of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-23-0825↗
  10. An evaluation of adjuvant chemotherapy following neoadjuvant chemotherapy and resection for borderline resectable and locally advanced pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2021.12.018↗
  11. Small molecule inhibitor against onco-mucins disrupts Src/FosL1 axis to enhance gemcitabine efficacy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215922↗
  12. Disruption of FDPS/Rac1 axis radiosensitizes pancreatic ductal adenocarcinoma by attenuating DNA damage response and immunosuppressive signalling. Co-author DOI 10.1016/j.ebiom.2021.103772↗
  13. Muc16 depletion diminishes KRAS-induced tumorigenesis and metastasis by altering tumor microenvironment factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-022-02493-6↗
  14. Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. Co-author DOI 10.1038/s41388-020-01564-w↗
  15. MASTL regulates EGFR signaling to impact pancreatic cancer progression. Co-author DOI 10.1038/s41388-021-01951-x↗
  16. Secretory Mucin 5AC Promotes Neoplastic Progression by Augmenting KLF4-Mediated Pancreatic Cancer Cell Stemness. Co-author DOI 10.1158/0008-5472.can-20-1293↗
  17. Mucin Expression and Splicing Determine Novel Subtypes and Patient Mortality in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1591↗
  18. Factors Predictive of Reoperation After Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.1007/s13193-019-00913-w↗
  19. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2019.03.056↗
  20. Inhibition of geranylgeranyl diphosphate synthase is a novel therapeutic strategy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-019-0794-6↗
  21. Selective Inhibition of Histone Deacetylases 1/2/6 in Combination with Gemcitabine: A Promising Combination for Pancreatic Cancer Therapy. Co-author DOI 10.3390/cancers11091327↗
  22. Cigarette Smoke Induces Stem Cell Features of Pancreatic Cancer Cells via PAF1. Co-author DOI 10.1053/j.gastro.2018.05.041↗
  23. Advanced pancreatic cancer: a meta-analysis of clinical trials over thirty years. Co-author DOI 10.18632/oncotarget.25036↗
  24. A Combination of MUC5AC and CA19-9 Improves the Diagnosis of Pancreatic Cancer: A Multicenter Study. First author DOI 10.1038/ajg.2016.482↗
  25. Neoadjuvant treatment of pancreatic adenocarcinoma: a systematic review and meta-analysis of 5520 patients. Co-author DOI 10.1186/s12957-017-1240-2↗
  26. Predictive global trends in the incidence and mortality of pancreatic cancer based on geographic location, socio-economic status, and demographic shift. Last author DOI 10.1002/jso.24410↗
  27. The canonical Wnt pathway regulates the metastasis-promoting mucin MUC4 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.molonc.2015.10.005↗
  28. MUC16 contributes to the metastasis of pancreatic ductal adenocarcinoma through focal adhesion mediated signaling mechanism. Co-author DOI 10.18632/genesandcancer.104↗
  29. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.6580↗
  30. Smoking accelerates pancreatic cancer progression by promoting differentiation of MDSCs and inducing HB-EGF expression in macrophages. Co-author DOI 10.1038/onc.2014.154↗
  31. Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells. Co-author DOI 10.18632/oncotarget.3308↗
  32. Changes in microRNA (miRNA) expression during pancreatic cancer development and progression in a genetically engineered KrasG12D;Pdx1-Cre mouse (KC) model. Co-author DOI 10.18632/oncotarget.5641↗
  33. Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisation. Co-author DOI 10.1038/bjc.2014.385↗
  34. MUC4-mediated regulation of acute phase protein lipocalin 2 through HER2/AKT/NF-κB signaling in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-13-2174↗
  35. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. Co-author DOI 10.1371/journal.pone.0055171↗
  36. Activated KrasG¹²D is associated with invasion and metastasis of pancreatic cancer cells through inhibition of E-cadherin. Co-author DOI 10.1038/bjc.2011.31↗
  37. Transcriptional profiling of peripheral blood mononuclear cells in pancreatic cancer patients identifies novel genes with potential diagnostic utility. Co-author DOI 10.1371/journal.pone.0017014↗
  38. Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer. Co-author DOI 10.3233/cbm-2012-0260↗

Closest collaborators

The 25 strongest of 124 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Surinder K. Batra · 27 shared papers, 2011–2026 · strength 2.35
  2. Randall E. Brand · 10 shared papers, 2011–2026 · strength 1.35
  3. Satyanarayana Rachagani · 18 shared papers, 2011–2024 · strength 1.33
  4. Pranita Atri · 10 shared papers, 2018–2024 · strength 1.17
  5. Moorthy Palanimuthu Ponnusamy · 12 shared papers, 2011–2024 · strength 1.12
  6. Maneesh Jain · 11 shared papers, 2011–2026 · strength 1.09
  7. Sushil Kumar K · 8 shared papers, 2011–2024 · strength 0.83
  8. Sanchita Rauth · 7 shared papers, 2018–2024 · strength 0.81
  9. Parthasarathy Seshacharyulu · 7 shared papers, 2016–2024 · strength 0.75
  10. Ashu Shah · 5 shared papers, 2021–2024 · strength 0.71
  11. Ann L. Oberg · 3 shared papers, 2024–2026 · strength 0.66
  12. Michael Goggins · 3 shared papers, 2024–2026 · strength 0.66
  13. Jesse L. Cox · 4 shared papers, 2021–2024 · strength 0.60
  14. Aatur Dilip Singhi · 2 shared papers, 2024–2026 · strength 0.54
  15. Sukhwinder Kaur · 9 shared papers, 2011–2022 · strength 0.53
  16. Rama Krishna Nimmakayala · 5 shared papers, 2018–2022 · strength 0.51
  17. Ramakanth Chirravuri‐Venkata · 4 shared papers, 2021–2022 · strength 0.44
  18. Christine Worthington · 2 shared papers, 2024–2026 · strength 0.44
  19. Imayavaramban Lakshmanan · 7 shared papers, 2014–2022 · strength 0.44
  20. Douglas W. Mahoney · 2 shared papers, 2024–2025 · strength 0.43
  21. Qiao-Li Wang · 2 shared papers, 2024–2025 · strength 0.43
  22. Gregory A. Coté · 2 shared papers, 2024–2025 · strength 0.43
  23. Michael Anthony Hollingsworth · 4 shared papers, 2014–2026 · strength 0.41
  24. Geoffrey A. Talmon · 4 shared papers, 2018–2022 · strength 0.40
  25. Chandrakanth Are · 5 shared papers, 2016–2019 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.